Your browser doesn't support javascript.
loading
A myeloid tumor suppressor role for NOL3.
Stanley, Robert F; Piszczatowski, Richard T; Bartholdy, Boris; Mitchell, Kelly; McKimpson, Wendy M; Narayanagari, Swathi; Walter, Dagmar; Todorova, Tihomira I; Hirsch, Cassandra; Makishima, Hideki; Will, Britta; McMahon, Christine; Gritsman, Kira; Maciejewski, Jaroslaw P; Kitsis, Richard N; Steidl, Ulrich.
Afiliação
  • Stanley RF; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Piszczatowski RT; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Bartholdy B; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Mitchell K; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • McKimpson WM; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Narayanagari S; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Walter D; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Todorova TI; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Hirsch C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH 44195.
  • Makishima H; Leukemia Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195.
  • Will B; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH 44195.
  • McMahon C; Leukemia Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195.
  • Gritsman K; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Maciejewski JP; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Kitsis RN; Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY 10461.
  • Steidl U; Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY 10461.
J Exp Med ; 214(3): 753-771, 2017 03 06.
Article em En | MEDLINE | ID: mdl-28232469
ABSTRACT
Despite the identification of several oncogenic driver mutations leading to constitutive JAK-STAT activation, the cellular and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood. Recent discoveries have identified underlying disease-modifying molecular aberrations contributing to disease initiation and progression. Here, we report that deletion of Nol3 (Nucleolar protein 3) in mice leads to an MPN resembling primary myelofibrosis (PMF). Nol3-/- MPN mice harbor an expanded Thy1+LSK stem cell population exhibiting increased cell cycling and a myelomonocytic differentiation bias. Molecularly, this phenotype is mediated by Nol3-/--induced JAK-STAT activation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and MycNol3-/- MPN Thy1+LSK cells share significant molecular similarities with primary CD34+ cells from PMF patients. NOL3 levels are decreased in CD34+ cells from PMF patients, and the NOL3 locus is deleted in a subset of patients with myeloid malignancies. Our results reveal a novel genetic PMF-like mouse model and identify a tumor suppressor role for NOL3 in the pathogenesis of myeloid malignancies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Supressoras de Tumor / Proteínas Reguladoras de Apoptose / Proteínas Musculares Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Supressoras de Tumor / Proteínas Reguladoras de Apoptose / Proteínas Musculares Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article